Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Nov 29, 2022 6:57pm
242 Views
Post# 35138184

RE:BTD application

RE:BTD application7 out of 7 newly treated patients seem to be CR at 90 days. In August 19 out of 38 evaluable patients were CR.  Today 26 out of 43 evaluable patients are CR.  Awesome improvements.IMO 

Aug  38 evaluable patients:        

19 CR  patients = 50% CR.         
6 PR patients = 16 % CR 
Total =66% responders

Nov. 43 evaluable patients 

26 CR patients = 60.4%
7  PR patients = 16.3%
Total responders = 77%

If we disgard 5 patients who were severely undertreated and dropped out of trial early before 2nd treatment , plus patient who died of unrelated Heart failure, then we could count 6 patients less.  ( that would still leave us with 7 undertreated patients in our data, but more realistic). That would be 26 CR out of 37, or 70.3% CR at 90 days, plus 7 out of 37, or 19% PR. For a realistic total responders at 89.2%. ( includes 7 undertreated patients). Total responders 26+7= 33 patients out of 37.  I'm speculating on what our data could look like without initial 12 undertreated patents.  Let's get AA in 2023 please.  All IMHO 
<< Previous
Bullboard Posts
Next >>